Approval Date: May 2023
Indicated for the control of absence (petit mal) seizures that are refractory to other drugs
Approval Date: May 2023
A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Approval Date: May 2023
Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19
Approval Date: May 2023
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes
Approval Date: May 2023
Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use
Approval Date: May 2023
Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages
Approval Date: May 2023
Indicated for the treatment of partial-onset seizures in adults
Approval Date: Apr 2023
Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder
Approval Date: Apr 2023
Indicated for the treatment of schizophrenia in adults
Approval Date: Mar 2023
Indicated for the acute treatment of migraine with or without aura
Approval Date: Mar 2023
Indicated for the short term management of mild to moderate acute pain
Approval Date: Feb 2023
Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine
Approval Date: Feb 2023
Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis
Approval Date: Jan 2023
Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease
Approval Date: Dec 2022
In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection
